Dec 11 (Reuters) - Eli Lilly said on Thursday its ‌next-generation ​obesity drug helped patients lose ‌an average of 28.7% of ...

Important state and national stories, market and business news, sports and entertainment, delivered in quick-hit fashion ...

Market sentiment has visibly soured. Year-to-date, the share price is down approximately 52%, and it has declined nearly 60% over a twelve-month period. The stock is trading close to its 52-week low, ...

The coming year, 2026, is shaping up as a critical operational and financial test. A head-to-head comparative study between Novo Nordisk's CagriSema and Eli Lilly's Zepbound, scheduled for 2026, will ...

Pharmacy benefit managers (PBMs) significantly impact GTN revenue through rebates, but patient access issues persist due to ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

At ASN Kidney Week 2025, Glucagon-like peptide-1 (GLP-1) receptor agonists moved firmly into the nephrology spotlight, with ...

Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Tariffs during President Trump's first term helped create jobs in and around Newberry, S.C. (Angela Owens/WSJ) During his first term, Trump imposed several tariffs, primarily targeting imports from ...